Fed. Circ. Ruling Reaffirms Listing Elements Separately Is Key
The U.S. Court of Appeals for the Federal Circuit's March 14 decision in Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. reaffirmed a critical principle in patent law: When a claim lists...To view the full article, register now.
Already a subscriber? Click here to view full article